Panchapakesan Usha, Pollock Carol, Saad Sonia
Renal Research Group, Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia.
Nephrology (Carlton). 2009 Apr;14(3):298-301. doi: 10.1111/j.1440-1797.2009.01089.x.
Thiazolidinediones (TZD) such as pioglitazone and rosiglitazone are proxisome proliferator-activated receptor gamma (PPARg) agonists and are widely used clinically to treat type 2 diabetes mellitus. Fluid retention still poses a significant limitation to its use. The primary renal process underlying TZD-associated oedema is reduced urinary sodium and water excretion. Experimental evidence suggests that this is mainly related to the effects of PPARg agonists on the distal nephron and collecting duct. We have recently shown that PPARg agonists upregulate sodium and water transport channels in human proximal tubule cells and that Sgk-1 is involved. In this review, we focus on the importance of the proximal tubular cells in TZD-mediated sodium and water uptake.
噻唑烷二酮类药物(TZD),如吡格列酮和罗格列酮,是过氧化物酶体增殖物激活受体γ(PPARγ)激动剂,在临床上广泛用于治疗2型糖尿病。液体潴留仍然是其使用的一个重大限制。TZD相关水肿的主要肾脏机制是尿钠和水排泄减少。实验证据表明,这主要与PPARγ激动剂对远端肾单位和集合管的作用有关。我们最近发现,PPARγ激动剂上调人近端肾小管细胞中的钠和水转运通道,且血清糖皮质激素调节激酶-1(Sgk-1)参与其中。在本综述中,我们重点关注近端肾小管细胞在TZD介导的钠和水摄取中的重要性。